PRX-03140 | 869493-21-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩并吡啶类
• 英文名称: PRX-03140
• 英文别名: 4-Hydroxy-7-isopropyl-6-oxo-n-(3-(1-piperidinyl)propyl)-6,7-dihydrothieno(2,3-b)pyridine-5-carboxamide；4-hydroxy-6-oxo-N-(3-piperidin-1-ylpropyl)-7-propan-2-ylthieno[2,3-b]pyridine-5-carboxamide
• CAS: 869493-21-0
• 化学式: C₁₉H₂₇N₃O₃S
• 分子量: 377.508
• InChiKey: SCHKZZSVELPJKU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  101
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  6,7-dihydro-4-hydroxy-7-isopropyl-6-oxo-N-(3-(piperidin-1-yl)propyl)thieno[2,3-b]pyridine-5-carboxamide hydrochloride salt 在 potassium penicillin V 作用下， 生成 PRX-03140
  参考文献：
  名称：

  US11725016

  摘要：

  公开号：

文献信息

• Thienopyridinone compounds and methods of treatment
  申请人：Dhanoa S. Dale

  公开号：US20050256153A1

  公开（公告）日：2005-11-17

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  该发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻吩吡啶酮化合物，以及其合成和用于治疗由5-HT受体直接或间接介导的疾病。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、促动力、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、心房颤动、缺血性中风、胃炎、胃排空障碍、进食障碍、消化道疾病、便秘、勃起功能障碍和呼吸抑制。还包括其制备方法、新颖中间体和药用盐。
• Synthesis of thienopyridinone compounds and related intermediates
  申请人：Dhanoa S. Dale

  公开号：US20060084805A1

  公开（公告）日：2006-04-20

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  本发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻唑吡啶酮化合物及其合成和用途，用于治疗直接或间接通过5-HT受体介导的疾病。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、胃肠动力障碍、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、房颤、缺血性中风、胃炎、胃排空障碍、进食障碍、胃肠道疾病、便秘、勃起功能障碍和呼吸抑制。还包括制备方法、新型中间体和药物盐。
• Thienopyridinone Compounds and Methods of Treatment
  申请人：Dhanoa Dale S.

  公开号：US20090163537A1

  公开（公告）日：2009-06-25

  The invention relates to 5-HT receptor agonists and partial agonists. Novel thienopyridinone compounds represented by Formula I, and synthesis and uses thereof for treating diseases mediated directly or indirectly by 5-HT receptors, are disclosed. Such conditions include Alzheimer's disease, cognition disorders, irritable bowel syndrome, nausea, emesis, vomiting, prokinesia, gastroesophageal reflux disease, nonulcer dyspepsia, depression, anxiety, urinary incontinence, migraine, arrhythmia, atrial fibrillation, ischemic stroke, gastritis, gastric emptying disorders, feeding disorders, gastrointestinal disorders, constipation, erectile dysfunction, and respiratory depression. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.

  本发明涉及5-HT受体激动剂和部分激动剂。公开了由式I表示的新型噻唑吡啶酮化合物及其合成和用于治疗直接或间接由5-HT受体介导的疾病的用途。这些疾病包括阿尔茨海默病、认知障碍、肠易激综合征、恶心、呕吐、胃肠动力障碍、胃食管反流病、非溃疡性消化不良、抑郁症、焦虑症、尿失禁、偏头痛、心律失常、房颤、缺血性中风、胃炎、胃排空障碍、进食障碍、胃肠道疾病、便秘、勃起功能障碍和呼吸抑制。还包括制备方法、新型中间体和药物盐。
• Hydantoins that modulate bace-mediated app processing
  申请人：Buck Institute for Research on Aging

  公开号：US10202355B2

  公开（公告）日：2019-02-12

  In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.

  在某些实施方案中，本文提供的海因化合物可有效抑制 BACE 对 APP 的活性。在不拘泥于特定理论的前提下，我们认为本文所确定的海因的活性似乎与 BACE 和/或 APP 的结合有关，特别是当这些分子形成 BACE/APP 复合物时。因此，我们认为本文所述的化合物代表了一类新的化合物，本文将其命名为 APP 结合-BACE 抑制剂 (ABBI)，并提供了一种调节 APP 处理过程的新机制。本文所述的 hydantoins 似乎具有更好的脑渗透性和功能性 BACE 抑制作用。
• Hydantoins that modulate BACE-mediated APP processing
  申请人：Buck Institute for Research on Aging

  公开号：US10766867B2

  公开（公告）日：2020-09-08

  In certain embodiments hydantoin compounds are provided herein that are effective to inhibit BACE activity against APP. Without being bound to a particular theory, it is believed the activity of the hydantoins identified herein appears to be associated with binding to BACE and/or to APP particularly when these moieties form a BACE/APP complex. Accordingly, it is believed the compounds described herein represent a new class of compounds designated herein as APP-Binding-BACE Inhibitors (ABBIs) and provide a new mechanism to modulate APP processing. The hydantoins described herein appear to show improved brain permeability and functional BACE inhibition.

  在某些实施方案中，本文提供的海因化合物可有效抑制 BACE 对 APP 的活性。在不拘泥于特定理论的前提下，我们认为本文所确定的海因的活性似乎与 BACE 和/或 APP 的结合有关，特别是当这些分子形成 BACE/APP 复合物时。因此，我们认为本文所述的化合物代表了一类新的化合物，本文将其命名为 APP 结合-BACE 抑制剂 (ABBI)，并提供了一种调节 APP 处理过程的新机制。本文所述的 hydantoins 似乎具有更好的脑渗透性和功能性 BACE 抑制作用。